SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Karrmann Sandra R

(Last)

(First)

(Middle)

1445 ROSS AVENUE

SUITE 1400

(Street)

DALLAS

75202

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/01/2019

3. Issuer Name and Ticker or Trading Symbol
TENET HEALTHCARE CORP [ THC ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP and Chief HR Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,971	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
2018 February Restricted Stock Units	⁽¹⁾	⁽¹⁾	Common Stock⁽²⁾	8,091	⁽²⁾	D
2018 February Performance Stock Options (Right to Buy)	⁽³⁾	02/28/2028	Common Stock	28,313	$20.6	D
2019 February Restricted Stock Units	⁽⁴⁾	⁽⁴⁾	Common Stock⁽²⁾	9,437	⁽²⁾	D
2019 February Performance Stock Options (Right to Buy)	⁽⁵⁾	02/27/2029	Common Stock	21,351	$28.26	D

Explanation of Responses:

1. Half of these time-based restricted stock units vest on each of February 28, 2020 and 2021.

2. Restricted stock units are settled in shares of the Company's common stock upon vesting.

3. These performance-based stock options will vest on February 28, 2021, as the stock price performance condition has been satisfied.

4. One-third of these time-based restricted stock units vest on each of February 27, 2020, 2021 and 2022.

5. These performance-based stock options vest on February 27, 2022, subject to the satisfaction of a stock price performance condition requiring the Company's common stock price to close at or above $35.33 per share for any 20 consecutive trading days during the three-year period following the date of grant, which was February 27, 2019.

Remarks:

	Anthony L. Shoemaker, as Attorney-in-Fact for Sandra R. Karrmann	03/11/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.